Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

Similar articles for PubMed (Select 24943384)

1.

Treatment and outcomes of invasive fusariosis: review of 65 cases from the PATH Alliance(®) registry.

Horn DL, Freifeld AG, Schuster MG, Azie NE, Franks B, Kauffman CA.

Mycoses. 2014 Nov;57(11):652-8. doi: 10.1111/myc.12212. Epub 2014 Jun 18.

2.

The Prospective Antifungal Therapy Alliance(®) registry: A two-centre Canadian experience.

Haider S, Rotstein C, Horn D, Laverdiere M, Azie N.

Can J Infect Dis Med Microbiol. 2014 Spring;25(1):17-23.

3.

Hema e-Chart registry of invasive fungal infections in haematological patients: improved outcome in recent years in mould infections.

Nosari AM, Caira M, Pioltelli ML, Fanci R, Bonini A, Cattaneo C, Castagnola C, Capalbo SF, De Fabritiis P, Mettivier V, Morselli M, Pastore D, Aversa F, Rossi G, Pagano L; Hema e-Chart Group, Italy.

Clin Microbiol Infect. 2013 Aug;19(8):757-62. doi: 10.1111/1469-0691.12014. Epub 2012 Dec 22.

4.

Clinical characteristics and outcomes in 303 HIV-infected patients with invasive fungal infections: data from the Prospective Antifungal Therapy Alliance registry, a multicenter, observational study.

Marukutira T, Huprikar S, Azie N, Quan SP, Meier-Kriesche HU, Horn DL.

HIV AIDS (Auckl). 2014 Mar 13;6:39-47. doi: 10.2147/HIV.S53910. eCollection 2014.

5.

International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole.

Lortholary O, Obenga G, Biswas P, Caillot D, Chachaty E, Bienvenu AL, Cornet M, Greene J, Herbrecht R, Lacroix C, Grenouillet F, Raad I, Sitbon K, Troke P; French Mycoses Study Group.

Antimicrob Agents Chemother. 2010 Oct;54(10):4446-50. doi: 10.1128/AAC.00286-10. Epub 2010 Jul 12.

6.

The PATH (Prospective Antifungal Therapy) Alliance® registry and invasive fungal infections: update 2012.

Azie N, Neofytos D, Pfaller M, Meier-Kriesche HU, Quan SP, Horn D.

Diagn Microbiol Infect Dis. 2012 Aug;73(4):293-300. doi: 10.1016/j.diagmicrobio.2012.06.012. Review.

PMID:
22789847
7.
8.

Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014.

Blyth CC, Gilroy NM, Guy SD, Chambers ST, Cheong EY, Gottlieb T, McGuinness SL, Thursky KA.

Intern Med J. 2014 Dec;44(12b):1333-49. doi: 10.1111/imj.12598.

PMID:
25482744
9.

Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions.

Raad II, Hachem RY, Herbrecht R, Graybill JR, Hare R, Corcoran G, Kontoyiannis DP.

Clin Infect Dis. 2006 May 15;42(10):1398-403. Epub 2006 Apr 11.

10.

Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry.

Steinbach WJ, Marr KA, Anaissie EJ, Azie N, Quan SP, Meier-Kriesche HU, Apewokin S, Horn DL.

J Infect. 2012 Nov;65(5):453-64. doi: 10.1016/j.jinf.2012.08.003. Epub 2012 Aug 13.

PMID:
22898389
11.

Changing epidemiology of rare mould infections: implications for therapy.

Malani AN, Kauffman CA.

Drugs. 2007;67(13):1803-12. Review.

PMID:
17722951
12.

Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.

Moen MD, Lyseng-Williamson KA, Scott LJ.

Drugs. 2009;69(3):361-92. doi: 10.2165/00003495-200969030-00010. Review.

PMID:
19275278
13.

Fusarium infection: report of 26 cases and review of 97 cases from the literature.

Muhammed M, Anagnostou T, Desalermos A, Kourkoumpetis TK, Carneiro HA, Glavis-Bloom J, Coleman JJ, Mylonakis E.

Medicine (Baltimore). 2013 Nov;92(6):305-16. doi: 10.1097/MD.0000000000000008. Review.

PMID:
24145697
14.

Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998-2009.

Campo M, Lewis RE, Kontoyiannis DP.

J Infect. 2010 May;60(5):331-7. doi: 10.1016/j.jinf.2010.01.010. Epub 2010 Feb 4.

PMID:
20138081
15.

Human fusariosis.

Dignani MC, Anaissie E.

Clin Microbiol Infect. 2004 Mar;10 Suppl 1:67-75. Review.

PMID:
14748803
16.

Earlier diagnosis of invasive fusariosis with Aspergillus serum galactomannan testing.

Nucci M, Carlesse F, Cappellano P, Varon AG, Seber A, Garnica M, Nouér SA, Colombo AL.

PLoS One. 2014 Jan 28;9(1):e87784. doi: 10.1371/journal.pone.0087784. eCollection 2014.

17.

Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients.

Bhatti Z, Shaukat A, Almyroudis NG, Segal BH.

Mycopathologia. 2006 Jul;162(1):1-15. Review.

PMID:
16830186
18.

Fusariosis, a complex infection caused by a high diversity of fungal species refractory to treatment.

Guarro J.

Eur J Clin Microbiol Infect Dis. 2013 Dec;32(12):1491-500. doi: 10.1007/s10096-013-1924-7. Epub 2013 Aug 11. Review.

PMID:
23934595
19.

Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.

Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J, Pfaller M, Chang C, Webster K, Marr K.

Clin Infect Dis. 2009 Feb 1;48(3):265-73. doi: 10.1086/595846. Erratum in: Clin Infect Dis. 2009 Mar 1;48(5):690.

20.

Surveillance of Aspergillus galactomannan antigenemia for invasive aspergillosis by enzyme-linked immunosorbent assay in neutropenic patients treated for hematological malignancies.

Ulusakarya A, Chachaty E, Vantelon JM, Youssef A, Tancrède C, Pico JL, Bourhis JH, Fenaux P, Munck JN.

Hematol J. 2000;1(2):111-6.

PMID:
11920178
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk